NEW YORK (GenomeWeb News) – Genetic Technologies today announced an agreement under which healthcare providers that participate in the network of managed healthcare plan MultiPlan will offer access to GTG's BrevaGen breast cancer test.
The deal, executed by GTG's wholly owned subsidiary Phenogen Sciences, provides the company access to MultiPlan's network of 4,800 hospitals, 99,000 ancillary facilities, and 700,000 healthcare professionals across the US. MultiPlan is headquartered in Valencia, Calif., and covers approximately 39 million lives, GTG noted.
The agreement is the sixth reached between Melbourne, Australia-based GTG and a US preferred provider organization. In total, 62 million covered lives in the US now have access to the company's BrevaGen test as an in-network service, the firm said. Earlier this month, it inked a deal with the Three Rivers Provider Network.
The DNA-based BrevaGen test evaluates the presence or absence of common SNPs associated with an increased risk for developing breast cancer.
Financial and other terms of the deal were not disclosed.